New drug combo targets rare, tough kidney cancers

NCT ID NCT06302569

Recruiting now Disease control Sponsor: Giuseppe Procopio Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 29 times

Summary

This study tests a combination of two drugs, pembrolizumab and enfortumab vedotin, for people with rare and aggressive kidney cancers (collecting duct carcinoma and renal medullary carcinoma). About 23 adults with advanced or metastatic disease will receive the treatment for several cycles. The main goal is to see how many patients experience tumor shrinkage. Researchers will also monitor side effects and how long the benefits last.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL MEDULLARY CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Fondazione Irccs Istituto Dei Tumori Di Milano
RECRUITING

Milan, 20133, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BELLINI CARCINOMA BELLINI CARCINOMA COLLECTING DUCT CARCINOMA RENAL MEDULLARY CARCINOMA